New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium

    * Aromasin:  Efficacy in the Treatment of Early Breast Cancer
      Data from the National Surgical Adjuvant Breast and Bowel Project
      (NSABP) B-33 study evaluates postmenopausal women with hormone receptor-
      positive breast cancer who, after five years of tamoxifen therapy,
      received either Aromasin or placebo.

    * Ellence:  Interim Analysis of Women with High Risk Node Negative Breast
      Cancer
      A study comparing the efficacy of several common chemotherapy regimens,
      including Ellence, cyclophosphamide, and fluorouracil (CEF), Ellence and
      cyclophosphamide followed by paclitaxel (ECT) and a combination of
      doxorubicin and cyclophosphamide followed by paclitaxel (AC/T).

    * Sutent:  Clinical Trials in Breast Cancer
      A phase III randomized open-label study of sunitinib malate in
      combination with paclitaxel versus bevacizumab with paclitaxel as a
      first-line treatment for patients with advanced breast cancer is now
      open and enrolling patients. The trial will enroll more than 700
      patients at 20 sites across the United States. The initiation of a
      second phase III trial is expected in early 2007. In addition, a phase
      II randomized, open-label study of sunitinib malate versus standard-of-
      care for patients with previously treated advanced triple receptor
      negative (ER-, PR- and HER2-) breast cancer is currently enrolling
      patients at 44 international sites, including more than 25 U.S. sites.
      For more information about this trial, visit
      http://www.pfizeroncology.com/clinicaltrialpo.aspx or call 1-877-369-
      9753.

    Key data presentations include:

    PRODUCT              TIME            ABSTRACT TITLE
    AROMASIN®                          Benefit from exemestane as extended
    (exemestane          Dec. 15         adjuvant therapy after five years of
    tablets)             9:30 am         tamoxifen: intent-to-treat analysis
                                         of NSABP B-33

    ELLENCE®                           A Randomized Trial of CEF versus Dose
    (epirubicin          Dec. 17         Dense EC followed by Paclitaxel
    hydrochloride        8:45 am         versus AC followed by Paclitaxel in
    injection)                           women with node positive or high risk
                                         node negative breast cancer, NCIC CTG
                                         MA.21: Results of an interim analysis